Navigation Links
Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008

28 New Contracts Valued at $115.5 Million Signed in Fourth Quarter

SUNNYVALE, Calif., Aug. 19 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today financial results for the fourth quarter and fiscal year ended June 28, 2008.

For the fourth quarter of fiscal 2008, Accuray reported total revenue of $50.9 million, a 16 percent increase over fourth quarter of fiscal 2007 total revenue of $44.0 million. For the fiscal year ended June 28, 2008, total revenue was $210.4 million, a 50 percent increase over the $140.5 million in total revenue for the fiscal year ended June 30, 2007.

Net income for the fourth quarter of fiscal 2008 was $191,000, or breakeven on a per diluted share basis, compared to net income of $502,000, or $0.01 per diluted share, in the fourth quarter of fiscal 2007. Net income for fiscal year 2008 was $5.4 million, or $0.09 per diluted share, compared to a net loss of $5.6 million, or $0.18 per diluted share, for the fiscal year 2007.

Non-cash, stock based compensation charges for the fourth quarter of fiscal 2008 were $4.1 million, or $0.07 per diluted share. For the full fiscal year 2008, non-cash stock-based compensation charges were $16.9 million, or $0.28 per diluted share.

During the fourth quarter of fiscal 2008, the company signed 28 new contracts with a value of $115.5 million which were entered into backlog. Of the 28 contracts, 17 came from international customers.

At June 28, 2008, backlog was approximately $647 million, with approximately $359 million associated with CyberKnife(R) Robotic Radiosurgery System contracts and approximately $288 million associated with services and other recurring revenue. Accuray's backlog is composed of signed contracts that the company believes have a substantially high probability of being recognized as revenue in future periods. Of the $647 million in backlog at fiscal year end, 71 percent consisted of non-contingent contracts, representing backlog for which contractual contingencies have been satisfied.

Accuray's cash and investment balances at the end of the quarter totaled $159.5 million, consisting of cash and cash equivalents of $36.9 million, short-term investments of $85.5 million and long-term investments of $37.0 million. At the end of the fourth quarter the company continued to have zero debt.

"We ended the fiscal year with strong momentum in new contracts and the quality of our sales pipeline, confirming the growing demand for our CyberKnife Robotic Radiosurgery System," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "Cancer patients, physicians and hospitals worldwide are benefiting from the non-invasive, painless, outpatient treatment offered by our System."


The following statement is forward-looking and actual results may differ materially. Accuray expects revenue for fiscal 2009 to be in the range of $230 million to $250 million.

Additional Information

Additional information regarding backlog segmentation which will be discussed during the conference call, is available in the Investor Relations section of the corporate Web site at

Earnings Call Open to Investors

Accuray will hold a conference call for financial analysts and investors today, August 19, 2008 at 2:00 p.m. PT / 5:00 p.m. ET. The conference call dial-in numbers are (866) 575-6539 (USA) or (913) 981-5530 (International), Access Code: 9058024. A live webcast of the call will also be available from the Investor Relations section of the corporate Web site at In addition, a recording of the call will be available by calling (888) 203-1112 (USA) or (719) 457-0820 (International), Access Code: 9058024, beginning at 5:00 p.m. PT / 8:00 p.m. ET, August 19, 2008 and will be available through August 29, 2008. A webcast replay will also be available from the Investor Relations section of the corporate Web site at from approximately 5:00 p.m. PT / 8:00 p.m. ET, today, through Accuray's release of its results for the first quarter of fiscal 2009, ending September 27, 2008.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non- invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 50,000 patients worldwide and currently 140 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, as to financial guidance including realization of backlog, procedure growth, market acceptance; clinical studies, regulatory review and approval, and commercialization of products are forward- looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; variability of installation and sales cycle including customer financing and construction delays; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2007 fiscal year, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission including our Form 10-K for fiscal 2008 when filed. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward- looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Accuray Incorporated

Unaudited Condensed Consolidated Statements of


(in thousands, except per share data)

Three months ended Years ended

June 28, June 30, June 28, June 30,

2008 2007 2008 2007

Net revenue:

Products $35,553 $34,729 $152,374 $110,320

Shared ownership programs 2,191 2,842 10,262 10,090

Services 11,842 5,651 38,808 16,860

Other 1,353 772 8,937 3,182

Total net revenue 50,939 43,994 210,381 140,452

Cost of revenue:

Costs of products 14,851 13,100 67,183 43,363

Costs of shared ownership

programs 290 672 2,517 2,637

Costs of services 7,851 4,781 26,865 12,269

Costs of other 1,051 525 6,864 2,144

Total cost of revenue 24,043 19,078 103,429 60,413

Gross profit 26,896 24,916 106,952 80,039

Operating expenses:

Selling and marketing 10,611 10,765 42,726 37,889

Research and development 8,405 7,510 32,880 26,775

General and administrative 8,460 7,060 32,280 23,915

Total operating expenses 27,476 25,335 107,886 88,579

Loss from operations (580) (419) (934) (8,540)

Interest and other income, net 1,030 2,180 7,184 3,530

Income (loss) before provision

for income taxes and

cumulative effect of change in

accounting principle 450 1,761 6,250 (5,010)

Provision for income taxes 259 1,259 867 1,444

Income (loss) before cumulative

effect of change in accounting

principle 191 502 5,383 (6,454)

Cumulative effect of change in

accounting principle, net - - - 838

of tax of $0

Net income (loss) $191 $502 $5,383 $(5,616)

Net income (loss) per common

share, basic and diluted:


Income (loss) before cumulative

effect of change in

accounting principle $0.00 $0.01 $0.10 $(0.21)

Cumulative effect of change in

accounting principle - - - 0.03

Basic net income (loss) per

share $0.00 $0.01 $0.10 $(0.18)


Income (loss) before cumulative

effect of change in

accounting principle $0.00 $0.01 $0.09 $(0.21)

Cumulative effect of change in

accounting principle - - - 0.03

Diluted net income (loss) per

share $0.00 $0.01 $0.09 $(0.18)

Weighted average common shares

outstanding used in computing

net income (loss) per share:

Basic 54,506 53,732 54,531 30,764

Diluted 58,854 62,553 60,434 30,764

Stock-Based Compensation Charges:

Cost of revenue, selling and marketing,

research and development, and general

and administrative expenses include

stock-based compensation charges as follows:

Cost of revenue $494 $357 $1,858 $1,205

Selling and marketing $970 $1,055 $4,197 $3,958

Research and development $781 $839 $3,059 $2,448

General and administrative $1,836 $1,604 $7,785 $5,016

Accuray Incorporated

Unaudited Condensed Consolidated Balance Sheets

(in thousands, except share amounts)

June 28, June 30,

2008 2007


Current assets:

Cash and cash equivalents $36,936 $204,830

Restricted cash 4,830 -

Short-term investments 85,536 -

Accounts receivable, net of allowance

for doubtful accounts of $27 and $20

at June 30, 2008 and 2007,

respectively 33,918 10,105

Inventories 23,047 16,984

Prepaid expenses and other current

assets 6,431 7,937

Deferred cost of revenue - current 31,667 30,709

Total current assets 222,365 270,565

Long-term investments 37,014 -

Property and equipment, net 17,140 23,937

Goodwill 4,495 4,495

Intangible assets, net 926 1,184

Deferred cost of revenue - noncurrent 11,724 30,522

Other assets 1,340 1,406

Total assets $295,004 $332,109

Liabilities and stockholders' equity

Current liabilities:

Accounts payable $12,962 $14,147

Accrued expenses 11,873 17,240

Customer advances - current 22,331 12,634

Deferred revenue - current 87,455 78,022

Total current liabilities 134,621 122,043

Long-term liabilities:

Customer advances - noncurrent 2,900 8,388

Deferred revenue - noncurrent 26,720 76,235

Total liabilities 164,241 206,666

Stockholders' equity

Preferred stock, $0.001 par value;

Authorized: 5,000,000 shares at both

June 30, 2008 and 2007; no shares

issued or outstanding. - -

Common stock, $0.001 par value

at both June 30, 2008 and 2007,

authorized: 100,000,000 shares at

both June 30, 2008 and 2007; issued:

56,719,864 and 53,798,643 shares at

June 30, 2008 and 2007, respectively;

outstanding: 54,579,846 and 53,798,643

shares at June 30, 2008 and 2007,

respectively. 55 53

Additional paid-in capital 252,901 251,637

Accumulated other comprehensive

income (loss) (1,067) 10

Accumulated deficit (121,126) (126,257)

Total stockholders' equity 130,763 125,443

Total liabilities and stockholders'

equity $295,004 $332,109

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Accuray Incorporateds CEO to Speak at Piper Jaffray 19th Annual Health Care Conference
2. Accuray Announces New Treatment Planning Service Offering
3. Accuray to Present at Citi Investment Research Small & Mid-Cap Conference
4. Accuray Wins Innovations in Healthcare(SM) ABBY Award
5. Accuray Incorporateds CEO to Speak at CitiGroup Healthcare Conference
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/12/2015)... LONDON , Nov. 11, 2015   ... and reliable analytical tools has been paving the ... and qualitative determination of discrete analytes in clinical, ... sensors are being predominantly used in medical applications, ... and environmental sectors due to continuous emphasis on ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):